What do systematic reviews say?

Direct thrombin inhibitors vs low molecular weight heparin

Direct thrombin inhibitors showed no clear difference in major VTE events bilateral ascending venography1 compared with low molecular weight heparins (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 0.91 [0.69, 1.19]
  11 studies · 17428 participants
  Low

Direct thrombin inhibitors vs low molecular weight heparin

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 2.06 [1.1, 3.87]
  11 studies · 22065 participants
  Moderate

Direct thrombin inhibitors vs low molecular weight heparin

Direct thrombin inhibitors showed no clear difference in total Bleeding events compared with low molecular weight heparins (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 1.17 [0.98, 1.41]
  11 studies · 22109 participants
  Low

Direct thrombin inhibitors vs low molecular weight heparin

Direct thrombin inhibitors may leads to lower ALT >3 times the upper normal limit compared with low molecular weight heparins (low certainty).

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
  OR 0.41 [0.23, 0.72]
  7 studies · 12580 participants
  Low

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

It is very uncertain whether systemic antibiotics plus antibiotic lock solutions plus tissue… changes cure: short‐term success compared with systemic antibiotics plus antibiotic lock solutions plus heparin (very low certainty).

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  RR 0.92 [0.74, 1.15]
  18 participants
  Very low

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

It is very uncertain whether systemic antibiotics plus antibiotic lock solutions plus tissue… changes cure: long‐term success compared with systemic antibiotics plus antibiotic lock solutions plus heparin (very low certainty).

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  RR 64 [0.38, 1.06]
  18 participants
  Very low

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  18 participants
  Very low

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thrombolytic therapy vs heparin: primary outcome measures

Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).

• Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
  OR 0.58 [0.38, 0.88]
  19 studies · 2319 participants
  Low

Thrombolytic therapy vs heparin: primary outcome measures

Thrombolytic therapy may leads to lower recurrence of pulmonary emboli (duration of compared with heparin: primary outcome measures (low certainty).

• Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
  OR 0.54 [0.32, 0.91]
  12 studies · 2050 participants
  Low

Thrombolytic therapy vs heparin: primary outcome measures

Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).

• Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
  OR 2.84 [1.92, 4.2]
  15 studies · 2101 participants
  Moderate

Thrombolytic therapy vs heparin: primary outcome measures

Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).

• Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only
  OR 2.97 [1.66, 5.3]
  13 studies · 1757 participants
  Low

Fondaparinux vs heparin

Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.81]
  1 study · 477 participants
  Low

Fondaparinux vs heparin

Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 0.93 [0.56, 1.54]
  1 study · 477 participants
  Low

Fondaparinux vs heparin

Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.4, 1.66]
  1 study · 477 participants
  Low

Fondaparinux vs heparin

Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  RR 1.53 [0.88, 2.66]
  1 study · 477 participants
  Moderate

Fondaparinux vs heparin

The review found no eligible studies for this question.

• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found